Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings and Inc.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Latest Pharmaceuticals and Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings, Inc. Stock News

As of September 1, 2026, Prestige Consumer Healthcare Inc. had a $2.5 billion market capitalization, compared to the Pharmaceuticals median of $654.2 million. Prestige Consumer Healthcare Inc.’s stock is down 13% in 2026, up 2.9% in the previous five trading days and down 22.63% in the past year.

Currently, Prestige Consumer Healthcare Inc.’s price-earnings ratio is 14.7. Prestige Consumer Healthcare Inc.’s trailing 12-month revenue is $1.1 billion with a 15.6% net profit margin. Year-over-year quarterly sales growth most recently was 6.5%. Analysts expect adjusted earnings to reach $4.568 per share for the current fiscal year. Prestige Consumer Healthcare Inc. does not currently pay a dividend.

As of September 1, 2026, Harmony Biosciences Holdings, Inc. had a $2.4 billion market cap, putting it in the 56th percentile of all stocks. Harmony Biosciences Holdings, Inc.’s stock is up 13.7% in 2026, up 7.2% in the previous five trading days and up 11.82% in the past year.

Currently, Harmony Biosciences Holdings, Inc.’s price-earnings ratio is 13.3. Harmony Biosciences Holdings, Inc.’s trailing 12-month revenue is $959.9 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was 30.3%. Analysts expect adjusted earnings to reach $5.222 per share for the current fiscal year. Harmony Biosciences Holdings, Inc. does not currently pay a dividend.

How We Compare Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings and Inc.’s Quality Grades

Company	Ticker	Quality
Prestige Consumer Healthcare Inc.	PBH	C
Harmony Biosciences Holdings, Inc.	HRMY	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Prestige Consumer Healthcare Inc. has a Quality Score of 57, which is Average. Harmony Biosciences Holdings, Inc. has a Quality Score of 91, which is Very Strong.

The Quality Grade Winner: Harmony Biosciences Holdings, Inc.

As you can clearly see from the Quality Grade breakdown above, Harmony Biosciences Holdings, Inc. has a better overall quality grade than Prestige Consumer Healthcare Inc.. For investors who are looking for companies with higher quality than others in the same industry, Harmony Biosciences Holdings, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings and Inc.’s Momentum Grades

Company	Ticker	Momentum
Prestige Consumer Healthcare Inc.	PBH	C
Harmony Biosciences Holdings, Inc.	HRMY	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Prestige Consumer Healthcare Inc. has a Momentum Score of 43, which is Average. Harmony Biosciences Holdings, Inc. has a Momentum Score of 71, which is Strong.

The Momentum Grade Winner: Harmony Biosciences Holdings, Inc.

As you can clearly see from the Momentum Grade breakdown above, Harmony Biosciences Holdings, Inc. is considered to have stronger momentum compared to Prestige Consumer Healthcare Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Harmony Biosciences Holdings, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Prestige Consumer Healthcare Inc.	PBH	C
Harmony Biosciences Holdings, Inc.	HRMY	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Prestige Consumer Healthcare Inc. has a Earnings Estimate Score of 43, which is Neutral. Harmony Biosciences Holdings, Inc. has a Earnings Estimate Score of 68, which is Positive.

The Earnings Estimate Revisions Grade Winner: Harmony Biosciences Holdings, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Harmony Biosciences Holdings, Inc. has a better Earnings Estimate Revisions Grade than Prestige Consumer Healthcare Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Harmony Biosciences Holdings, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings and Inc. Grades

In addition to Momentum, Quality and Estimate Revisions, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings or Inc. Stock?

Overall, Prestige Consumer Healthcare Inc. stock has a Momentum Score of 43, Estimate Revisions Score of 43 and Quality Score of 57.

Harmony Biosciences Holdings, Inc. stock has a Momentum Score of 71, Estimate Revisions Score of 68 and Quality Score of 91.

Comparing Prestige Consumer Healthcare Inc., Harmony Biosciences Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.